1/2
07:36 am
imcr
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development [Yahoo! Finance]
Low
Report
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development [Yahoo! Finance]
1/2
07:00 am
imcr
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Low
Report
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
12/26
03:14 pm
imcr
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 [Yahoo! Finance]
Low
Report
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 [Yahoo! Finance]
12/24
12:25 pm
imcr
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer [Yahoo! Finance]
Low
Report
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer [Yahoo! Finance]
12/23
09:17 am
imcr
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term [Yahoo! Finance]
Low
Report
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term [Yahoo! Finance]
12/23
07:17 am
imcr
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME [Yahoo! Finance]
Medium
Report
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME [Yahoo! Finance]
12/23
07:00 am
imcr
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Medium
Report
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
12/17
07:32 am
imcr
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers [Yahoo! Finance]
Low
Report
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers [Yahoo! Finance]
12/17
07:00 am
imcr
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Low
Report
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
12/13
08:05 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $74.00.
Low
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $74.00.
12/11
07:10 am
imcr
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma [Yahoo! Finance]
Low
Report
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma [Yahoo! Finance]
12/11
07:00 am
imcr
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
Low
Report
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
12/3
01:08 pm
imcr
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study [Yahoo! Finance]
Low
Report
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study [Yahoo! Finance]
12/3
12:03 pm
imcr
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada [Yahoo! Finance]
Low
Report
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada [Yahoo! Finance]
12/3
01:06 am
imcr
Immunocore announces reimbursement agreement in England for KIMMTRAK? for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma [Yahoo! Finance]
Medium
Report
Immunocore announces reimbursement agreement in England for KIMMTRAK? for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma [Yahoo! Finance]
12/3
01:00 am
imcr
Immunocore announces reimbursement agreement in England for KIMMTRAK? for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Medium
Report
Immunocore announces reimbursement agreement in England for KIMMTRAK? for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
11/28
11:38 am
imcr
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo [Yahoo! Finance]
Low
Report
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo [Yahoo! Finance]
11/26
12:03 pm
imcr
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma [Yahoo! Finance]
Low
Report
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma [Yahoo! Finance]
11/19
03:58 pm
imcr
FATE Presents Encourgaing Data From Lupus Study, Stock Gains [Yahoo! Finance]
Low
Report
FATE Presents Encourgaing Data From Lupus Study, Stock Gains [Yahoo! Finance]
11/19
09:14 am
imcr
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
Medium
Report
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
11/13
01:26 pm
imcr
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]
Low
Report
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]
11/11
07:47 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.
11/8
09:00 am
imcr
The Galien Foundation Honors 2024 Prix Galien Award Recipients
Medium
Report
The Galien Foundation Honors 2024 Prix Galien Award Recipients
11/8
07:00 am
imcr
Immunocore to present at upcoming investor conferences
Low
Report
Immunocore to present at upcoming investor conferences
11/7
08:36 am
imcr
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $78.00 to $71.00. They now have a "buy" rating on the stock.
Medium
Report
Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $78.00 to $71.00. They now have a "buy" rating on the stock.